Breast cancer therapy affects the expression of antineonatal Nav1.5 antibodies in the serum of patients with breast cancer-Reference-Cited by-同舟云学术

Breast cancer therapy affects the expression of antineonatal Nav1.5 antibodies in the serum of patients with breast cancer

Published:2020-12-11 Issue:2 Volume:21 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Rajaratinam Harishini¹^ORCID,Rasudin Nur Syahmina¹^ORCID,Al Astani Tengku Ahmad Damitri²^ORCID,Mokhtar Noor Fatmawati³,Yahya Maya Mazuwin⁴^ORCID,Wan Zain Wan Zainira⁴^ORCID,Asma‑Abdullah Nurul¹,Mohd Fuad Wan Ezumi¹^ORCID

Affiliation:

1. School of Health Sciences, Health Campus, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan 16150, Malaysia

2. Department of Chemical Pathology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan 16150, Malaysia

3. Institute for Research in Molecular Medicine (INFORMM), School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan 16150, Malaysia

4. Department of Surgery, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan 16150, Malaysia

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Cross-Reactivity of NaV Autoantibodies in Metastatic Breast Cancer: A Possible Trigger for Sudden Cardiac Death;2024-09-06

2. Circulating Neonatal NAV1.5 (nNAV1.5) Antigen and Anti-nNAV1.5 Antibodies as Potential Biomarkers for Breast Cancer Metastasis;Sains Malaysiana;2022-09-30

3. Immunotherapy in breast cancer treatment;Scaffold Press Books;2022-03-31

4. Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives;Biomolecules;2022-02-15

5. Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors;Cancer Immunology and Immunotherapy;2022